Please login to the form below

Not currently logged in
Email:
Password:

bladder cancer

This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.

J&J’s targeted bladder cancer treatment gets US approval

J&J’s targeted bladder cancer treatment gets US approval

AstraZeneca also has an FGFR candidate in a phase 1b trial for bladder cancer. ... Although FGFR inhibitors have been developed for use within bladder cancer, the drugs’ use could be extended into earlier-stage cancers, further expanding its potential

Latest news

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    It will be applied across all eight of Keytruda’s monotherapy indications in five tumour types, including non-small cell lung cancer (NSCLC), melanoma, bladder cancer, head and neck cancer and ... It made history by becoming the first FDA-approved drug

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    The EMA’s advisory committee gave a positive opinion on Vizimpro (dacomitinib) as a single-agent therapy for locally advanced or metastatic EGFR-positive non-small cell lung cancer (NSCLC), setting ... paclitaxel or nab-paclitaxel chemotherapy, while

  • Roche builds on Immunocore ImmTAC deal Roche builds on Immunocore ImmTAC deal

    The trial is scheduled to start in early 2019, and will include a host of cancers, including non-small cell lung cancer (NSCLC), bladder cancer, head and neck cancer, gastric cancer ... Those molecules are based on soluble, engineered TCR’s, which

  • AZ’s MYSTIC survival data is in – and it’s a bust AZ’s MYSTIC survival data is in – and it’s a bust

    Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and ... In the meantime, AZ also has trials of Imfinzi

  • Roche gains speedy review for Tecentriq in first-line breast cancer Roche gains speedy review for Tecentriq in first-line breast cancer

    Tecentriq in combination with nab-paclitaxel has the potential to meaningfully advance treatment for people with PD-L1-positive, metastatic triple-negative breast cancer. ... Tecentriq is already approved in the US for certain types of bladder cancer and

More from news
Approximately 20 fully matching, plus 94 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.

  • Deal Watch October 2015 Deal Watch October 2015

    Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer  (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... drug and the risk of bladder cancer.

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs).  . ... bladder cancer.

  • Achieving consensus

    Their joint aim: to facilitate uniform use of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer, with the ultimate goal of improved care and better outcomes for patients. ... Despite widespread acceptance of the evidence for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A reflection of ESMO

    The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics